Form 4: Keros Therapeutics Director Ran Nussbaum Acquires 10,000 Stock Options
SEC Form 4 Filing
Director Ran Nussbaum acquired 10,000 stock options in Keros Therapeutics, Inc. on May 30, 2024.
Summary
- Ran Nussbaum, a director of Keros Therapeutics, Inc., acquired 10,000 stock options on May 30, 2024.
- The exercise price of these options is $46.31.
- The options vest in equal quarterly installments over 12 months, fully vesting by the date of the Issuer's 2025 annual meeting of stockholders, contingent upon continued service.
- The options expire on May 29, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of stock option grants. The director's acquisition could be interpreted as a positive signal, but it's a routine part of compensation.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, common in the biopharmaceutical industry where stock options are frequently used as part of executive compensation packages.
Stakeholder Impact
- The acquisition of stock options by a director could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/30/2024 | Date of the stock option acquisition. |
| 05/29/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.